Qiming Venture Partners

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.

Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

Iongen Therepeutics is an innovative drug research and development company focusing on pain treatment.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.

Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.

LongBio Pharma is a biotechnology company focused on developing antibody-based biologics for autoimmune and allergic diseases. Its platform concentrates on complement and IgE pathways, aiming to provide affordable, high-quality treatments that enhance patients' access to more effective therapies.

Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor designed to treat patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) who have central nervous system metastases. Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consulting and management team to ensure rigorous research and development processes. The company emphasizes a multi-faceted approach to drug development, which includes research, market strategy, and intellectual property protection, while working closely with leading contract research organizations, contract manufacturing organizations, hospitals, and institutes to facilitate the orderly implementation of its projects.

Simaixu Biotechnology is a biopharmaceutical firm that develop small molecule drugs for cancer, and chronic diseases with new technologies

Novamab is a biotechnology company specializing in the development of novel nanobodies, a type of single-domain antibody with unique therapeutic advantages. With over 15 years of experience in nanobody research and development, the company's team of pioneers in this field has established platforms to maximize the potential of nanobodies. Novamab focuses on creating innovative drug formulations such as inhaled macromolecular drugs, albumin nanobody long-acting therapies, and nanobody double-antibody combinations. Their primary goal is to address unmet clinical needs by improving administration methods and reducing treatment cycles for major chronic diseases like cancer, autoimmune disorders, and cardiovascular conditions.

Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

GenEditBio is a biotechnology company dedicated to developing curative gene editing therapies for genetic disorders. It focuses on innovative in vivo gene editing tools and delivery systems.

CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.

Pinnacle Medicines is a biotechnology company based in Doylestown, Pennsylvania. It specializes in peptide drug discovery, utilizing AI-based tools to develop safe and effective therapeutics for unmet medical needs.

Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

AskGene Pharma is a biotechnology company developing novel cytokine prodrugs for oncology and autoimmune diseases. Its innovative smart kine prodrug platform overcomes challenges in current cytokine therapies, enabling safer and more effective treatments.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

Ailomics Therapeutics, established in 2022 with headquarters in Shanghai, China, specializes in developing novel drugs for treating immune diseases and tumors. The company employs a computational biology platform to analyze multi-omics patient data, aiming to uncover new drug targets and mechanisms driving disease progression.

CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. The company offers a range of vaccines, including a freeze-dried rabies vaccine for human use and an influenza virus split vaccine. CuroVax employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and mRNA vaccine development. It provides biotechnology and microbiology services, focusing on improving health and medical industry standards.

Satellos Bioscience is a private regenerative medicine company dedicated to developing innovative therapeutics aimed at stimulating or restoring muscle regeneration. The company is particularly focused on addressing severe disorders, with a key program centered on creating an oral therapeutic drug for Duchenne muscular dystrophy. This drug is designed to correct the dysregulation identified by Satellos as a fundamental cause of the disease's progressive nature. Through its research and development efforts, Satellos aims to provide effective treatments that enhance muscle regeneration and improve the quality of life for individuals affected by this debilitating condition.

Complete Omics is a company focused on the development of multi-omics diagnostics for early disease detection, particularly in cancer. The firm specializes in creating personalized diagnosis and treatment platforms that leverage advanced technologies across various omics fields. With patented innovations, Complete Omics offers precision companion diagnostics that enhance the ability to conduct sensitive and specific health surveillance tests. By enabling researchers and pharmaceutical companies to utilize these sophisticated tools, Complete Omics aims to improve diagnosis and treatment outcomes in the field of oncology.

Abdera is an oncology company developing targeted alpha therapies for patients with relapsed, refractory, or metastatic cancers. Its precision oncology platform integrates drug development and antibody engineering technologies to create novel radiopharmaceuticals that specifically target tumors while minimizing systemic toxicities.

Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

Caidya is a North Carolina-based clinical research organization that provides personalized solutions across therapeutic areas. It operates and develops a proprietary technology platform that integrates data from diverse systems to deliver near real-time visibility into clinical trials. Founded in 2021, Caidya offers advisory services on clinical development plans, regulatory strategies, approval processes, and trial execution, helping pharmaceutical and biotechnology companies globalize development, improve trial efficiency, and increase the likelihood of product success.

Allorion Therapeutics is a biopharmaceutical company specializing in the development of small molecule therapeutics for cancer and autoimmune diseases. Headquartered in Natick, Massachusetts, with operations in Guangzhou, China, Allorion focuses on innovative drug designs to enhance efficacy and mitigate patient resistance.

OriCell Therapeutics is a biopharmaceutical company that specializes in the development of innovative cellular drugs aimed at addressing unmet clinical needs in tumor immunotherapy. The company focuses on creating therapeutics for a range of cancers, including liver cancer, myeloma, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. With a commitment to effective and affordable treatment options, OriCell Therapeutics aims to enhance patient care through the development of clinically valuable therapies, seeking to establish itself as a leader in the field of novel oncological treatments.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Reunion Biotech focuses on the research and development and industrial transformation of medical hydrogels. The company is committed to becoming an international leading hydrogel technology platform. The current pipeline includes systemic solutions for tumor radiotherapy protection, wound repair, tumor embolization, and drug delivery.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

Core Medical (Beijing) Co., Ltd. is a contract research organization (CRO) founded in 2013 and based in Beijing, China. The company specializes in clinical professional services focused on new technologies and innovative products within the cardiovascular sector. Core Medical offers a range of services, including animal testing, type testing, First-in-Man (FIM) studies, human studies, and statistics and data management for clinical research. By providing these services, Core Medical helps companies in the cardiovascular field evaluate and validate their products, facilitating advancements in medical technology.

Ailomics Therapeutics, established in 2022 with headquarters in Shanghai, China, specializes in developing novel drugs for treating immune diseases and tumors. The company employs a computational biology platform to analyze multi-omics patient data, aiming to uncover new drug targets and mechanisms driving disease progression.

OriCell Therapeutics is a biopharmaceutical company that specializes in the development of innovative cellular drugs aimed at addressing unmet clinical needs in tumor immunotherapy. The company focuses on creating therapeutics for a range of cancers, including liver cancer, myeloma, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. With a commitment to effective and affordable treatment options, OriCell Therapeutics aims to enhance patient care through the development of clinically valuable therapies, seeking to establish itself as a leader in the field of novel oncological treatments.

OPUS develops clinically applicable tissue engineering products and treatments.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

RiboX Therapeutics is a biotech company that focuses on discovery and development of fully engineered circular RNA therapeutics.

LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.

Boulder Care, established in 2017 and headquartered in Portland, Oregon, specializes in telemedicine-based programs for opioid addiction treatment. The company offers comprehensive services including medication-assisted treatment with buprenorphine, peer support, patient counseling, and psychosocial services to aid recovery. Boulder Care serves patients directly, as well as healthcare providers and organizations seeking to expand access to effective opioid addiction treatment.

AskGene Pharma is a biotechnology company developing novel cytokine prodrugs for oncology and autoimmune diseases. Its innovative smart kine prodrug platform overcomes challenges in current cytokine therapies, enabling safer and more effective treatments.

LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

Curie.Bio is a Boston-based venture capital firm founded in 2022 that focuses on founder-led seed-stage investments in therapeutics companies.

Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Sinogen Biopharma is founded with a vision to bridge China's biotech innovation to the US pharma market. The company licenses and develops innovative drugs from China.

Allorion Therapeutics is a biopharmaceutical company specializing in the development of small molecule therapeutics for cancer and autoimmune diseases. Headquartered in Natick, Massachusetts, with operations in Guangzhou, China, Allorion focuses on innovative drug designs to enhance efficacy and mitigate patient resistance.

Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.

Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company offers a diverse range of products, including modified nucleotides, unnatural amino acids, heterocycles, as well as fluorescent and labeling reagents. Okeanos serves prominent pharmaceutical companies, delivering high-quality chemical compounds and intermediates that support various applications in research and development. Renowned for its commitment to quality and innovation, Okeanos has established a strong reputation among its clients in the pharmaceutical industry.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Genevide is a biotech company established in 2019 and based in Suzhou, Jiangsu, China. The company focuses on gene research and development, specifically addressing challenges in nucleic acid detection. Genevide has developed a molecular enzyme cycle screening platform that includes enzyme-mediated one-step sample processing technology and enzyme-mediated double exponential amplification nucleic acid detection technology. These innovations aim to enhance the accessibility and efficiency of nucleic acid detection for researchers.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.

Just Medical is a developer and manufacturer of artificial orthopedic implant devices and systems, specializing in products such as artificial hip and knee joints, internal fixation products, and orthopedic surgical instruments. The company is dedicated to enhancing surgical efficiency and improving the quality of orthopedic treatment through advanced technology research and development. Just Medical focuses on creating safe and effective medical products and services, continually refining its product system to address the needs of healthcare providers and alleviate patient pain. Its commitment to high-speed development and excellence positions it as a key player in the orthopedic medical device industry.

Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor designed to treat patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) who have central nervous system metastases. Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consulting and management team to ensure rigorous research and development processes. The company emphasizes a multi-faceted approach to drug development, which includes research, market strategy, and intellectual property protection, while working closely with leading contract research organizations, contract manufacturing organizations, hospitals, and institutes to facilitate the orderly implementation of its projects.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

OriCell Therapeutics is a biopharmaceutical company that specializes in the development of innovative cellular drugs aimed at addressing unmet clinical needs in tumor immunotherapy. The company focuses on creating therapeutics for a range of cancers, including liver cancer, myeloma, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. With a commitment to effective and affordable treatment options, OriCell Therapeutics aims to enhance patient care through the development of clinically valuable therapies, seeking to establish itself as a leader in the field of novel oncological treatments.

Kira Pharmaceuticals, established in 2017 and headquartered in Suzhou, China, is a biotechnology company focused on developing innovative therapies targeting the complement system to treat immune-mediated diseases.

Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.

LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Elevation Oncology develops precision medicines for genomically defined cancers. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions, currently in Phase 2 trials.

Kira Pharmaceuticals, established in 2017 and headquartered in Suzhou, China, is a biotechnology company focused on developing innovative therapies targeting the complement system to treat immune-mediated diseases.

Asieris Pharmaceuticals Co. Ltd. is a biotechnology company based in Taizhou, China, founded in 2010. The company is dedicated to the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. By focusing on oncology and infectious diseases, Asieris Pharmaceuticals seeks to develop innovative therapies that meet the medical needs of patients both in China and globally.